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Effect of acetazolamide on renal metabolism and ammoniagenesis in the
dog. The effect of acetazolamide (ACZ) on renal metabolism and
ammoniagenesis was studied in the dog in vivo and in vitro. ACZ was
administered to 10 dogs with normal acid—base status and five with
chronic metabolic acidosis induced by NH4CI. In both groups of dogs,
the acute administration of ACZ markedly reduced the urinary excre-
tion of ammonium (from 33 to 10 in normal dogs and from 100 to 23
tmoles/l00 ml GFR in acidotic dogs) whereas its release into the renal
vein was increased in a reciprocal fashion (from 69 to 95 in normal dogs
and from 91 to 152 smoles/l00 ml GFR in acidotic dogs). ACZ did not
change the total ammonium production nor the renal glutamine utiliza-
tion. The renal utilization or production of glutamate, alphaketoglutar-
ate, alanine and citrate also remained unchanged. Despite a marked
urinary alkalinization, citraturia remained minimal. However, the renal
cortical concentrations of glutamine, glutamate, succinate, fumarate,
malate, aspartate and phosphoenolpyruvate fell following ACZ admin-
istration, especially in acidotic dogs showing rapid renal utilization of
glutamine. ACZ had no effect on the same metabolites in the kidney of
normal dogs even when lactate utilization was enhanced by lactate
infusion. This study demonstrates that an accelerated ammoniagenic
flux can proceed in the dog kidney without the renal cortical changes
produced by metabolic acidosis in this species. In vitro, using dog
tubules, a selective effect of ACZ on glutamine metabolism as com-
pared to lactate was observed. ACZ reduced the rate of the reactions
catalyzed by alphaketoglutarate dehydrogenase and by succinyl CoA
synthetase. Other enzymes of the ammoniagenic and gluconeogenic
pathways (glutaminase, GLDH, malic enzyme, PEPCK) were not
changed by ACZ. The metabolic effects of ACZ observed in the intact
kidney in vivo or with tubules in vitro may be in part related to the effect
of ACZ on these enzymes critical for the ammoniagenic process.
The marked bicarbonaturia and urinary alkalinization result-
ing from the acute administration of acetazolamide, a carbonic
anhydrase inhibitor, is accompanied by a drastic reduction of
urinary ammonium excretion [1]. In man, the ammonium re-
lease into the renal vein simultaneously increases whereas total
ammonium production remains unchanged [2]. It has been
therefore suggested that the reduced ammoniuria simply re-
flects a diversion of the renal cellular ammonium production
from an alkaline urine to the renal venous blood [2, 3].
By contrast, the decreased urinary—ammonium excretion has
also been attributed to a reduced renal ammoniagenesis in the
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rat [4] and in the dog [5]. It has been postulated that
acetazolamide could depress in the dog the activity of glutamate
dehydrogenase [5], whereas in the rat a direct inhibition of
cytoplasmic [4] or mitochondrial [6] glutaminase, cytoplasmic
y-glutamyltransferase [4] and y-glutamyltranspeptidase [7] ac-
tivity has been suggested. However these enzymatic inhibitions
remain controversial because Chapman and Hoover [8] failed to
reproduce them in a more recent study. Tannen and Ross [9]
have shown recently that 0.1 ms acetazolamide decreased
ammonium production by 22% in the isolated perfused rat
kidneys, and also reduced glomerular filtration rate (GFR) by
33%. Nevertheless a decreased gluconeogenesis was observed
and proposed as the possible mechanism responsible for the
reduced ammoniagenesis [9]. A slight anti-ammoniagenic effect
of acetazolamide has also been reported in renal cortical tubules
isolated from normal or acidotic rats [9].
The present study was undertaken to determine whether the
reduced urinary ammonium excretion in alkaline urine of dogs
receiving acetazolamide simply reflects a shift of ammonium
from an alkaline urinary compartment to the renal venous blood
(unchanged renal ammoniagenesis) or results from a decreased
renal ammoniagenesis. If a reduced renal ammoniagenesis is
indeed observed in dogs following acetazolamide, this may
suggest that acetazolamide modifies the metabolism of proximal
tubular cells, either by alkalinizing the intracellular and/or
intramitochondrial pH, or by altering the relative contribution
of ammoniagenic (glutamine) and non-ammoniagenic (lactate
and citrate) substrates to the production of energy in proximal
tubular cells [10]. Thus the renal utilization or production of
various metabolites was also monitored before and during
acetazolamide administration.
Our results in normal and acidotic dogs indicate that the
absolute renal glutamine utilization and ammonium production
decreased modestly following acetazolamide administration.
However, most of this reduction can be accounted for by the
concomitant fall in GFR induced by acetazolamide. Therefore,
when expressed per 100 ml GFR, renal glutamine utilization and
ammoniagenesis remained virtually unchanged during acetazol-
amide administration, urinary ammonium being simply diverted
into the renal vein. Quite unexpectedly, acetazolamide reduced
the renal cortical concentrations of succinate, fumarate, malate
and aspartate in chronically acidotic dogs despite the acceler-
ated glutamine metabolism. Additional in vivo and in vitro
experiments show that this effect occurs specifically on the
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pathways of glutamine metabolism and could reflect a reduced
flux between glutamine and malate, possibly related to an
observed inhibition by acetazolamide of alphaketoglutarate
dehydrogenase and succinyl CoA synthetase, and also a de-
creased flux between malate and glucose. These enzymatic
changes affect the maximal ammoniagenic flux studied in vitro,
but have limited consequences on this flux in vivo.
Methods
in vivo studies
Studies were performed on 16 normal and six chronical-
ly—acidotic mongrel dogs ranging in weight from 19 to 48 kg
(average wt, 28 kg). Chronic metabolic acidosis was induced by
the daily administration of ammonium chloride (10 g/day) for at
least five days. Food was withheld during 16 hours before
anesthesia but free water intake was allowed. The dogs were
anesthetized with intravenous sodium pentobarbital (30 mg/kg)
and received additional small doses whenever necessary during
the experiments. A cuffed tube was inserted into the trachea
and connected to a Harvard respirator. The rate and depth of
respiration were adjusted to maintain arterial carbon dioxide
tension (PCO2) around 40 mm Hg.
Renal utilization or production of substrates and metabolites
profile of the renal cortex before and after acetazolamide.
Eighteen studies were carried out on 13 normal and five
chronically acidotic dogs. After a priming dose of creatinine (20
mg/kg of body wt), a solution composed of half isotonic
mannitol and half isotonic sodium chloride and containing I g of
creatinine and 1 g of p-aminohippurate (PAH) per liter was
adjusted to pH 7.0, and infused into a jugular vein at a constant
rate of 4 ml/min which was reduced to 2 mI/mm following right
nephrectomy. The abdominal cavity was opened through a
midline incision and the left renal vein was catheterized under
direct inspection after ligation of the left ovarian or spermatic
vein; the left ureter was also catheterized and urine was
collected under mineral oil. During this surgical procedure,
each dog received 300 ml of isotonic saline. During the exper-
iment, blood was drawn anaerobically through a femoral artery
catheter and analyzed immediately for acid—base parameters.
A tissue sample of the right kidney cortex was obtained and
instantaneously freeze—clamped between two aluminum blocks
cooled to the temperature of liquid nitrogen according to the
technique of Wollenberger, Ristau and Schoffa [11]. The inter-
val between removal of the renal tissue and the freeze—clamping
procedure was always less than five seconds. The right renal
pedicle was ligated immediately after this procedure and the left
kidney was studied. Following a 30-minute equilibration period,
the renal utilization of glutamine, lactate, pyruvate, alpha-
ketoglutarate and citrate and the renal production of ammo-
nium, glutamate, alanine and aspartate by the left kidney were
measured by three determinations of arteriovenous differences
and four consecutive 10-minute urine collections.
Maximal carbonic anhydrase inhibition was then induced by
a priming dose of 20 mg of acetazolamide/kg followed by a
maintenance dose of 20 mg/kg per hour [12]. Immediately
following the administration of the priming dose of acetazol-
amide, twelve consecutive, 10-minute urine collections brack-
eted by seven determinations of arteriovenous differences were
obtained. As soon as the last blood sample had been drawn, that
is, after 120 minutes of acetazolamide administration, a tissue
sample from the remaining left kidney was freeze-clamped as
described above and the animal was sacrificed. The renal
cortical metabolites were thus measured before and after 120
minutes of acetazolamide administration.
In a control group of three normal dogs not receiving
acetazolamide, the same protocol was followed in order to rule
out an eventual contribution of the surgical and experimental
procedures to the reductions in renal blood flow, GFR, renal
glutamine utilization and ammoniagenesis or to the changes in
the renal utilization or production of other metabolites. Com-
parable data have been reported, in part, in a previous study
[13].
Additional in vivo studies. To gain further understanding on
the mechanisms and the specificity of the effect of acetazol-
amide, four additional experiments were performed in vivo. In
three dogs with normal acid—base equilibrium, the specificity of
the effect of acetazolamide on glutamine metabolizing pathways
was studied by measuring cortical concentrations of critical
metabolites in the kidney metabolizing lactate instead of
glutamine. Arterial and renal cortical concentrations of lactate
were acutely increased by the infusion of a solution containing
equal parts of 0.6 M sodium L-lactate and of 0.6 M L-lactic acid
at a rate of 10 mEq/kg/hr for 60 minutes. Arterial blood was
drawn and a tissue sample of the right kidney cortex was then
instantaneously freeze-clamped [11] for the measurement of the
critical metabolites profile-changes induced by lactate infusion.
A priming dose of 20 mg of acetazolamide/kg followed by a
maintenance dose of 20 mg/kg/hr was then given, and the rate of
infusion of the lactate/lactic acid solution was reduced to 6
mEq/kg/hr. After 60 minutes of acetazolamide administration,
another arterial blood sample was drawn and a tissue sample
from the remaining left kidney was freeze-clamped.
In order to evaluate the effect of the increased tissue pNH3
observed following acetazolamide administration, the renal
cortical metabolites were measured in a chronically acidotic
dog before (in the right kidney) and after (in the left kidney) the
acute rise in arterial blood ammonium—concentration induced
by the direct infusion into the left renal artery of a 0.1 M
ammonium chloride solution at a rate of 1 mI/mm during 60
minutes.
in vitro studies
Effect of acetazolamide on the metabolism of isolated kidney
tubules incubated with glutamine, lactate, alphaketoglutarate,
succinate or ,nalate. Cortical tubules were prepared from the
kidney cortex of 12 normal dogs by collagenase digestion of
tissue slices according to a procedure already described [14].
Approximately 30 mg of tubules were incubated in a final
volume of 4 ml of gassed (95% 02—5% C02) Krebs—Henseleit
saline containing 2.5 g% of dialyzed bovine albumin (fraction V)
and adjusted to pH 7.4 or 7.1 by varying the bicarbonate
concentration (substitution with equimolar amounts of sodium
chloride). In eight experiments, the incubation medium con-
tained either glutamine 2 mM/glutamate 0.2 m or lactate 2
mM/pyruvate 0.2 m (in the presence or absence of 1 mM
NH4CI in four of these studies) as substrates for the tubules. In
four additional experiments, the incubation medium contained
either 2 mri alphaketoglutarate, 2 mi succinate or 2 mr'i
malate. For each condition, 0, 0.1 or 1 mr'i acetazolamide was
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present in the flasks in order to study acetazolamide concentra-
tions in the vicinity of those previously observed in vivo in the
plasma [15] or in the renal cortex [12] of the dog. The flasks
were incubated for 0 or 60 minutes at 37°C with constant
shaking (40 rpm), and the incubation was stopped by the
addition of 40% perchloric acid (final concentration of 5%). The
acid supernatant was neutralized with potassium hydroxide and
used to determine the concentration of glutamine, glutamate,
alphaketoglutarate, ammonium, succinate, malate, aspartate,
lactate, alanine and glucose by enzymatic assays as previously
reported [13]. Uptake or production of each metabolite was
calculated using corresponding zero—time values and expressed
per g wet weight and per 60 minutes of incubation.
Measurement of enzymatic activities. The possible influence
of various concentrations of acetazolamide (from 0.01 to 2mM),
ammonium (from 0.1 to 10 mM) and bicarbonate (from 6.25 to 50
mM) on various enzymatic activities (glutaminase, glutamate
dehydrogenase [GLDH], alphaketoglutarate dehydrogenase,
succinyl CoA synthetase, malic enzyme and phosphoenol-
pyruvate carboxykinase [PEPCK]) was tested on dog kidney
cortex. Various concentrations of bicarbonate were used to
investigate an eventual effect of an acetazolamide induced
change in cytosolic or intramitochondrial bicarbonate concen-
tration on the enzymes of renal glutamine metabolism. Enzy-
matic activities were expressed as moles of substrates trans-
formed per gram of fresh tissue per minute, and also as
percentages of the activity observed in the absence of acetazol-
amide, ammonium or bicarbonate.
Analytical methods
The pH of blood and urine was measured anaerobically at
38°C with a digital acid—base analyzer (Radiometer, model
PHM 72). Analytical methods used to determine carbon dioxide
content, sodium, potassium, chloride, phosphate, creatinine,
and PAH concentrations have been described previously [16,
17]. The frozen tissues were pulverized and extracted with four
volumes of 10% wt/vol perchloric acid per gram of tissue.
Concentration of metabolites was measured on a neutralized
extract of deproteinized blood, urine or tissue by methods
previously reported [13]. The rate of the reactions catalyzed by
phosphate—dependent glutaminase [14, 18], GLDH [19], alpha-
ketoglutarate dehydrogenase [20], succinyl CoA synthetase
[21], malic enzyme [22] and PEPCK (measured in the forward
direction, that is, phosphoenolpyruvate generation [23, 24])
present in homogenates of dog kidney cortex was studied by the
following procedure: kidney cortices were homogenized in 10
volumes of 0.25 M ice—cold sucrose containing 5 mrvi Tris-HCI
and 1 mr'i dithiothreitol (adjusted to pH 8.0) by four passes of a
motor-driven Teflon pestle. No attempt was made to separate
mitochondrial and cytoplasmic enzymatic activities. The enzy-
matic activities were "solubilized" by freezing and thawing
three times [25]. Samples were stored in ice and assayed the
same day. All assays were carried out at 37°C using at least two
different concentrations of proteins.
Calculations
Plasma carbon-dioxide tension and bicarbonate concentra-
tion were calculated from the Henderson—Hasselbalch equation
using a solubility coefficient of 0.0301 and a pK' of 6.10 for
carbonic acid. For urine, a solubility coefficient of 0.0309 was
used while the pK' was 6.33 — 0.5 V(Na)+(K), the concen-
trations of Na and K being expressed in equivalents per liter
[26]. Exogenous creatinine clearance was used to estimate
glomerular filtration rate (GFR). Renal blood flow was calcu-
lated from the PAH clearance (corrected for renal extraction)
and the hematocrit value. Renal utilization or production of
each metabolite took into account the net urinary losses accord-
ing to the Wolf s equation as modified by Cohen [27] for
substances utilized or produced by the kidney. To quantify the
renal utilization of substrates at comparable rates of sodium
filtration and reabsorption, the renal utilization or production of
metabolites was also expressed per 100 ml GFR. The rationale
of this calculation was fully explained in a recent publication
[28]. Renal cortical ammonium concentration was calculated
from the renal vein ammonium—concentration [29]. In in vivo
and in vitro studies, the metabolic fates of glutamine were
dissected out as recently described [10]. The enzymatic activi-
ties were determined by calculating the slope of product ac-
cumulation as a function of time by the least squares method.
The data lines with various concentrations of acetazolamide
were presented as double—reciprocal plots of Lineweaver—Burk
and calculated by regression analysis. The Michaelis—Menten
constant Km, the maximum velocity Vmax and the inhibi-
tor (acetazolamide) constant Ki were calculated in the usual
manner.
Statistical analysis
Unless otherwise specified, the term significant is used
throughout the paper to describe a difference with a P value of
less than 0.05. A two-way variance analysis for repeated
measurements on one level was performed, comparisons of all
mean values being obtained by the Newman—Keuls procedure
[30]. When specified, some comparisons were also made using
Student's t-test for paired or unpaired data whenever applica-
ble.
Results
In vivo studies
Renal utilization or production of substrates and metabolites
profile of the renal cortex before and after acetazolamide.
Blood and urine values. Temporal changes in blood and urine
parameters before and during acetazolamide administration are
depicted in Table 1. Acetazolamide reduced slightly the mean
arterial blood pH from 7.40 to 7.34 in normal dogs and from 7.17
to 7.10 in chronically acidotic dogs, decrements resulting from
the modest rise in arterial PCO2. Plasma potassium concentra-
tion averaged 3.9 mEq/liter throughout the experiments. As
expected, acetazolamide induced a rapid and marked urinary
alkalinization, the mean fractional bicarbonate excretion in-
creasing from 2% to 35% in normal dogs which were slightly
volume—expanded by the isotonic saline infused slowly into
their left renal vein. In dogs with chronic metabolic acidosis,
acetazolamide induced only a modest urinary alkalinization, the
mean fractional bicarbonate excretion increasing only to 12%.
This finding agrees with the well—known reduction of the
bicarbonaturic effect of acetazolamide during metabolic acido-
sis [31, 32]. Acetazolamide increased fractional water excretion
from 4% to 11% in normal dogs and from 4% to 7% in
chronically acidotic dogs. In both groups of dogs mean glomer-
1282 Gougoux et at
Table 1. Effect of acetazolamide on blood and urine parameters
Plasma
Blood pH
Arterial PCO2
mm Hg
bicarbonate
mM Urine pH
CHCO,/GFR
%
Citraturia
pmo1Imin
GFR
mi/mm
RBF
mi/mm
Normal dogs (N = 10)
Control —40—0 mm 7.40 0.01 34 0.6 20.5 0.5 6.90 0.13 2 0.6 0.07 0.02 28 3 200 19
Acetazolamjde 0—40 mm 7.38 0.01 37 1° 20.9 0.5 7.65 0.04° 35 3° 0.09 0.01 23 2° 180 19
Acetazolamide 40—80 mm 7.35 0.01° 38 ia 20.5 0.5 7.62 0.04° 36 3° 0.08 0.01 22 2° 143 isa
Acetazolamide 80—120 mm 7.34 0.01° 39 ia 20.1 0.5 7.54 0.04a 35 3° 0.08 0.01 20 2° 131 15°
Acidotic dogs (N = 5)
Control —40—0 mm 7.17 0.03 37 2 13.2 1.0 5.56 0.24 0.7 0.5 0.07 0.02 33 4 298 49
Acetazolamide 0—40 mm 7.14 0.03 43 2° 14.1 0.8 7.10 0.07° 14 4 0.09 0.02 28 4 272 51
Acetazolamide 40—80 mm 7.12 0.04° 46 2° 14.3 0.7 6.99 0.14° 12 4 0.08 0.02 25 5° 222 44
Acetazolamide 80—120 mm 7.10 0.04° 49 3° 14.8 0.8 6.91 0,19° 12 4° 0.08 0.03 24 5° 191 40°
Values are means SE and are calculated from the means of three (during the control period) and two (during the experimental periods) blood
values and from the means of four 10-mm urinary collections.
a Significant difference from the mean control value (P < 0.05)
Table 2. Effect of acetazolamide on renal metabolism
Renal
Arterial
glutamine
mM
Glutamine
utilization
vein
NH4
release UNH4V
Total NH4
production
Lactate
utilization
pinol/min
Pyruvate
util/prod
Citrate
utilization
Glutamate
production
Alanine
production
Normal dogs (N = 10)
Control —40—0 mm 0.55 0.04 —18 2 18 2 9 2 27 3 —17 7 —1 0.4 —8 1 2 0.4 16 2
Acetazolamide 0—40mm 0.49±0.03° —16±2 19±2 2±0.3° 21±2° —22±5 —1±0.5 —6±1 2±0.3 13±1
Acetazolamide40—80min 0.51 0.03 —14 1 19 2 2 0.2° 21 2° —18 4 0 0.2 —6 1 2 0.2 10 2°
Acetazolamide 80—120 mm 0.54 0.03 —IS 1 18 2 2 0.2° 20 1° —17 5 —l 0.6 —6 1 2 0.3 11 2°
Acidotic dogs (N = 5)
Control —40—0 mm 0.74 0.07 —31 6 30 4 34 7 64 10 —27 6 +3 1 —6 1 3 1 12 2
Acetazolamide 0—40 mm 0.67 0.06 —31 7 43 9 9 2° 52 ioa —25 10 +4 1 —6 1 3 1 14 3
Acetazolamide 40—80 mm 0.62 0.05a —19 4 37 9 4 1° 41 9° —22 9 +3 1 —5 I 2 I 8 2
Acetazolamide 80—120 mm 0.61 0.05° —20 4 35 8 4 ia 39 8° —18 8 +4 1 —5 I 2 I 7 2
Values are means SE and are calculated from the means of four 10-mm urinary collections.
a Significant difference from the mean control value (P < 0.05)
ular filtration rate fell by almost 30% following acetazolamide
infusion whereas mean renal blood flow decreased by approx-
imately 35%. In control dogs not receiving acetazolamide, GFR
fell by only 8% and in a non-significant fashion from 51 to 47
mi/mm (the mean weight of these three dogs being 40 kg).
Urinary citrate excretion remained minimal (<0.10 xmol/
mm) and virtually unchanged by acetazolamide administration.
Urinary excretion of glutamine (<0.07 tmol/min), glutamate
(<0.02 jxmol/min), alphaketoglutarate (<0.01 xmollmin), ma!-
ate (<0.002 prnollmin in acidotic dogs), aspartate (<0.01
xmol/min in acidotic dogs) and pyruvate (<0.06 mol/min)
remained minimal before and after acetazolamide administra-
tion whereas urinary excretion of lactate (<0.45 prnol/min) was
not changed significantly by acetazolamide infusion.
Renal utilization or production of metabolites. Renal
glutamine utilization fell modestly but not significantly from a
mean control value of 18 to 15 imol/min during acetazolamide
administration in dogs with normal acid—base equilibrium and
from 31 to 20 molImin in dogs with chronic metabolic acidosis
(Table 2). However, renal glutamine utilization per 100 ml GFR
remained virtually unchanged during acetazolamide administra-
tion (Table 3). Renal ammoniagenesis was significantly reduced
from a mean control value of 27 to 20 amol/min durine
acetazolamide infusion in dogs with normal acid—base equilib-
rium and from 64 to 39 in chronically acidotic dogs. However
when expressed per 100 ml GFR this parameter remained
unchanged in normal dogs and was reduced by only 8% and in
a non-significant fashion in acidotic dogs (Fig. 1, Table 3). The
ratio of ammonium production over glutamine utilization was
not changed by acetazolamide, remaining around 1.4 in normal
dogs and around 2.0 in chronically acidotic dogs. The fractions
of glutamine either supporting amino acid (glutamate, alanine,
aspartate) production or deamidated to glutamate and deamin-
ated by GLDH to alphaketoglutarate were not changed by
acetazolamide in acidotic dogs, whereas the GLDH fraction
remained minimal in normal dogs. The urinary alkalinization
resulting from acetazolamide reduced markedly the fraction of
ammonium excreted into the urine to approximately 10% of the
total ammonium production, but increased in a reciprocal
fashion the fraction released into the renal vein from 68 to 90%
in normal dogs and from 48 to 87% in acidotic dogs (Fig. 1,
Table 3). In control dogs not infused with acetazolamide, renal
glutamine utilization and ammoniagenesis remained virtually
unchanged, whereas the distribution of ammonia between the
urinary comDartment and the renal venous blood did not
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Table 3. Effect of acetazolamide on renal utilization or production of metabolites
Normal dogs Acidotic dogs
Control AcetazolamideControl Acetazolamide(N = 40) (N = 120) (N = 20) (N = 60)
Utilization
Glutamine —69 5 —74 3 93 7b —96 6
Lactate —64 13 —99 8 —64 18 —76 18
Pyruvate —5 I —2 P
Alphaketoglutarate —1 0.3 —0.4 0.2 —l 0.5 —l 0.2
Citrate —30 2 —28 1 —19 —22 1
Production
NH4 102±7 105±4 1916b 175±8
—Renal vein 69 6 95 4 91 9b 152 7
—Urine 33 3 10 P 100 6b 23 2
Glutamate 7 1 9 1 9 2 8 I
Aspartate I 1 0.4 0.4 10 1b 3 P
Alan me 59 3 53 2 39 4b 46 4
Pyruvate — — 12 2" 16 2
Values are smol/100 ml GFR and are means SE; N = number of 10-mm experimental periods.
a Significant difference (P < 0.05) from control value, the comparisons being made with the Student's (-test for unpaired data
"Significant difference (P < 0.05) between control values in normal and acidotic dogs, the comparisons being made with the Student's (-test for
unpaired data
change. Comparable control data have been previously re-
ported, in part [13].
Only in normal dogs with a marked bicarbonaturia, but not in
acidotic dogs with a more modest bicarbonaturia, acetazol-
amide modestly increased renal lactate utilization per 100 ml
GFR but slightly reduced pyruvate utilization per 100 ml GFR.
No significant changes in the utilization of alphaketoglutarate
and citrate or in the production of glutamate were induced by
acetazolamide (Tables 2 and 3). Aspartate production remained
minimal in normal dogs but acetazolamide reduced it from 10 to
3 jzmoles/100 ml GFR in chronically acidotic dogs. Alanine
production fell modestly during acetazolamide infusion in both
groups of dogs (Table 2) but this parameter did not change
significantly when expressed per 100 ml GFR (Table 3). No
significant release of malate into the renal vein was observed
before and during acetazolamide administration. In control
dogs not receiving acetazolamide, the renal utilization or pro-
duction of other metabolites did not change.
Metabolites profile of the renal cortex (Table 4). Chronic
metabolic acidosis induced the concentration changes in critical
metabolites expected in the kidney cortex of chronically
acidotic dogs: a fall in glutamate, alphaketoglutarate and cit-
rate, and a steep rise in fumarate, malate and aspartate concen-
trations. Following acetazolamide administration, renal cortical
glutamine concentration fell significantly from a control value of
0.69 to 0.39 tmolIg in normal dogs and from 0.64 to 0.39 mo1/g
in chronically acidotic dogs, this value of 0.39 jzmollg being
close to the arterial glutamine concentrations of 0.54 and 0.61
mM, respectively. Glutamate concentration also fell signifi-
cantly in normal dogs, whereas in chronically acidotic dogs
acetazolamide markedly reduced succinate, fumarate, malate,
aspartate and phosphoenolpyruvate concentrations and slightly
increased citrate concentration. The concentrations of the other
relevant metabolites of the ammoniagenic and gluconeogenic
pathways did not change significantly from control values.
In control dogs not infused with acetazolamide, the renal
cortical concentrations of various metabolites did not change.
Comparable control data have been reported previously [13].
Thus acetazolamide reduced significantly the renal cortical
concentration of critical metabolites in chronically acidotic
dogs with rapid renal glutamine metabolism without changing
the flux in the ammoniagenic pathways (when expressed per 100
ml GFR). However, because the actual flux was reduced by
acetazolamide (a change resulting presumably from hemody-
namic changes), additional studies with acetazolamide were
performed in vivo and in vitro.
Additional in vivo studies. The effect of acetazolamide on the
Normal dogs Acidotic dogs
Control
10
ACZ ACZ
Fig. 1. Total ammonia production in Amoles per 100 ml GFR before
and during acetazolamide (ACZ) administration in 10 dogs with normal
acid—base equilibrium and in five dogs with chronic metabolic acidosis
induced by NH4CI. Values are means SE of 40 (normal dogs) or 20
(acidotic dogs) control periods and of 120 (normal dogs) or 60 (acidotic
dogs) periods obtained following acetazolamide administration. Sym-
bols are: the renal venous (LI) and the urinary (g) components.
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Table 4. Metabolites profile of the renal cortex before and after acetazolamide
Normal dogs (N = 10) Acidotic dogs (N = 5)
Control Acetazolamide Control Acetazolamide
Glutamine 0.69 0.08 0.39 0.06 0.64 0.14 0.39 0.O4
Glutamate 5.18 0.23 4.07 0.16a 2.82 0.17" 2.53 0.29
a-ketoglutarate 0.09 0.02 0.08 0.01 0.01 0.005" 0.01 0.01
Ammonium (calculated) 0.47 0.02 0.56 0.03" 0.46 0.02 0.68 0.08
Succinate — — 0.31 0.06 0.19 0.03
Fumarate 0.014 0.004 0.02 0.003 0.15 003b 0.04 0.01"
Malate 0.13 0.02 0.14 0.02 0.% 0.16" 0.26 0.06a
Oxaloacetate: MDH-LDH 2.63 2.58 4.81 0.96
(calculated) GOT 2.75 3.14 2.03 0.74
Aspartate 1.06 0.07 1.07 0.09 3.84 0.68" 1.25 0.20"
Lactate 0.62 0.08 0.68 0.12 0.50 0.08 0.68 0.19
Pyruvate 0.05 0.01 0.05 0.01 0.01 0.01" 0.01 0.01
Alanine 1,01 0.08 0.91 0.09 1.23 0.12 0.83 0.15
Citrate 0.24 0.01 0.23 0.03 0.14 0.03" 0.18 0.03a
Acetoacetate 0.07 0.01 0.06 0.01 0 0" 0 0
13-Hydroxybutyrate 0.03 0.003 0.03 0.005 0.01 0.01 0.01 0.01
Phosphoenolpyruvate 0.06 0.004 0.05 0.004 0.09 0.02 0.05 0.01"
2-Phosphoglycerate 0.04 0.004 0.04 0.004 0.05 0.02 0.04 0.01
3-Phosphoglycerate 0.05 0.004 0.05 0.004 0.05 0.02 0.05 0.01
Glucose-6-phosphate 0.04 0.004 0.04 0.002 0.06 0.01 0.06 0.01
ATP 1.42 0.04 1.14 0.08 1.51 0.07 1.44 0.03
ADP 0.79 0.04 0.71 0.05 0.63 0.07 0.53 0.04
AMP 0.20 0.02 0.17 0.01 0.14 0.04 0.12 0.02
Inorganic phosphate 4.12 0.84 3.98 0.68 2.61 0.21 2.56 0.20
Values are means SE (number of dogs). Results are expressed as micromoles per gram wet weight.
"Significant difference (P < 0.05) from control value, the comparisons being made with the Student's i-test for paired data
b Significantdifference (P < 0.05) between control values in normal and acidotic dogs, the comparisons being made with the Student's i-test for
unpaired data
Table S. Metabolites profile of the renal cortex before and after
acetazolamide in lactate—loaded dogs
Control Acetazolamide
Glutamine 0.68 0.25 0.62 0.33
Glutamate 4.35 0.29 4.88 0.27
Fumarate 0.08 0.01 0.08 0.01
Malate 0.33 0.01 0.35 0.05
Aspartate 0.53 0.09 0.37 0.02
Lactate 7.00 2.10 7.74 0.27
Pyruvate 0.17 0.01 0.24 0.04
Phosphoenolpyruvate 0.05 0.03 0.06 0.01
Values are means SE in three dogs. Results are expressed as
micromoles per gram wet weight. No significant differences could be
detected between the control values and those obtained following
acetazolamide administration, the comparisons being made with the
Student's i-test for paired data.
renal cortical metabolites profile of normal dogs loaded with
lactate (arterial concentration of 9.8 2.6 mM) to induce a rapid
renal metabolism of this substrate was also investigated.
Acetazolamide did not change arterial blood pH (7.48 before
and 7.47 after acetazolamide), whereas arterial blood PCO2
(from 40.4 to 45.7 mm Hg) and plasma bicarbonate concentra-
tion (from 29.3 to 32.2 mEq/liter) increased slightly. Renal
cortical lactate concentration rose to 7.0 moles/g wet weight
with appropriate elevation of tissue pyruvate. Tissue fumarate
and malate increased markedly because of pyruvate carboxyl-
ase activation (as compared to acidotic dogs in which this
increment results from the faster metabolism of glutamine).
Aspartate concentration was reduced by lactate infusion (Table
5), possibly because of the rapid alanine synthesis induced by
this maneuver. Despite hemodynamic effects comparable to
those observed in dogs rapidly metabolizing glutamine,
acetazolamide did not significantly change the concentration of
any of the relevant metabolites measured in these lactate—
loaded dogs in which the increased renal cortical concentrations
of malate and oxaloacetate resulted from lactate instead of
chronic metabolic acidosis. More specifically, glutamine, fuma-
rate, malate, aspartate and phosphoenolpyruvate were not
reduced by acetazolamide.
Because acetazolamide increased the renal cortical PNH3
from 64 to 81 x 106 mm Hg in chronically acidotic dogs, we
also investigated if this rise per se could be directly responsible
for the observed fall in the renal cortical concentrations of
critical metabolites. A threefold rise in the renal venous blood
ammonium concentration from 0.19 to 0.54 m was induced by
an acute infusion of ammonium chloride into the renal artery,
and failed to reproduce the changes in metabolites induced by
acetazolamide.
In vitro studies
Effect of acetazolamide on the metabolism of isolated kidney
tubules. Cortical tubules incubated with glutamine or lactate.
The addition of acetazolamide to the incubation medium con-
taining 2 mrvi glutamine modestly reduced glutamine utilization
and ammonia production by tubules suspension obtained from
the cortex of normal dogs. Simultaneously, an increased
glutamate accumulation was noted, as previously reported in
the rat [9]. These changes were of greater magnitude with
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Table 6. Effect of acetazolamide on kidney tubules of normal dogs
Initial substrates Acetazolamide
concentration and concentration
incubation pH mivi
Metabolites production (+) or uptake (—)
Glutamine Glutamate Ammonia Malate Aspartate Lactate Alanine Glucose
Glutamine 2 mM/Glutamate 0.2 mM
—62 11
—66 10
—60 9
33 4
36 339 4
106 698 385 3
0.08 0.08
0.01 0.04
0.00 0.05
0,6 0.5
0.5 0.5
—0.5 0.3a
1.4 0.5
1.1 0.5
0.3 0.4a
4.4 0.5
4.8 0.5
4.9 0.7
10
9
7
I
I
ia
PH7.4
0
0.1
1
PH 7.1
0
0.1
1
—77 10
—65 7
—60 I0
28 232 242 2
122 4
109 389 6
0.15 0.10
0.09 0.06
0.05 0.09
3.6 0.7
2.5 0.5
0.5 0.4a
2.2 0.5
1.9 0.60.7 0,4
6.9 0.7
7.2 0.7
6.2 1.4
14
12
7
1
1i
Lactate 2 mM/Pyruvate 0.2 mM
0.0 0.1
0.4 0.4
—0.6 0.2
9 1
Il 1
12 ia
11 I
10 I
11 I
—0.03 0.08
0.04 0.06
0.47 0.IOa
—5,7 0.8
—5.6 0.8
—5.6 0.7
—84 8
—81 9
—79 8
19 1
19 1
17 ia
24
23
18
I
I
ia
PH 7.4
0
0.1
1
PH 7.1
0
0.1
1
—0.6 0.3
—0.2 0.3
—0.2 0.2
6 I7 P
11 ia
13 1
10 0.4a
10 0.5a
—0.11 0.03
0.04 0.04
0.37 0.lla
—5.7 0.8
—5.3 0.8
—5.8 0.8
—90 10
—80 9
—75 9
20 2
22 2
20 1
26
24
20
1
1
ia
Values are means SE (N = 8 dogs). Results are expressed as micromoles per gram wet weight per 60 minutes and are corrected for zero time.
A positive sign represents production of a metabolite whereas a negative sign depicts uptake.
a Significant difference from value obtained in the absence of acetazolamide in the flask (P < 0.05)
tubules incubated at pH 7.1 (Table 6). Malate and aspartate
accumulation were reduced by the addition of acetazolamide, a
fall reminiscent of the marked reduction in the renal cortical
concentrations of malate and aspartate induced in vivo by
acetazolamide in chronically acidotic dogs. Glucose (as previ-
ously reported in the rat [9]) and lactate production from
glutamine fell whereas alanine production did not change.
When the tubules were incubated at pH 7.4, acetazolamide
reduced the fraction of glutamine metabolized through the
GLDH pathway from 24 to 16.6 jsmol/g wet wt/60 mm, whereas
this component was decreased from 38 to 11 when the tubules
were incubated at pH 7.1. By contrast, the fraction of glutamine
converted to amino acids increased from 38 to 43.4 (pH 7.4) and
from 38.5 to 48.7 when the incubation medium had a pH of 7.1.
With 2 m lactate in the medium, acetazolamide modestly
reduced lactate utilization and gluconeogenesis, increased
glutamate and malate accumulation and at an incubation pH of
7.1 reduced ammonia production from endogenous sources
(Table 6). With either glutamine or lactate as substrate the
addition of NH4C1 1 m (not shown in Table 6) did not induce
any significant change in the uptake or production of metabo-
lites, suggesting that an increased PNH3 could not reproduce
the effects of acetazolamide. It should be pointed out however
that the effects observed in vitro are of modest amplitude.
Cortical tubules incubated with aiphaketoglutarate, suc-
cinate or malate. In an attempt to pinpoint the site(s) of action
of acetazolamide on the ammoniagenic pathway, the metabo-
lism of various intermediates of this pathway was studied with
or without acetazolamide. With 2 ms alphaketoglutarate as
substrate, the addition of acetazolamide significantly reduced
alphaketoglutarate utilization, malate production and gluconeo-
genesis (Table 7). When 2 mri succinate was the substrate,
acetazolamide also modestly reduced succinate utilization, mal-
ate production and gluconeogenesis. With 2 mM malate as
substrate, the addition of acetazolamide still significantly re-
duced gluconeogenesis (as previously reported in the rat [9]) as
well as malate utilization.
Measurement of enzymatic activities. The rate of the reac-
tions catalyzed by glutaminase and by glutamate dehydrog-
enase was not modified by the addition of various concentra-
tions of acetazolamide or ammonium chloride, nor by changes
in the bicarbonate concentration in the incubation medium
(without simultaneous pH changes due to the strong buffering
capacity of the medium). However progressive concentrations
of acetazolamide up to 2 m reduced from 0.92 to 0.27
smol/g/min the rate of the reaction catalyzed by alphaketoglu-
tarate dehydrogenase (Fig. 2A). The double—reciprocal plots of
Lineweaver—Burk indicated a competitive inhibition of acetazol-
amide on alphaketoglutarate dehydrogenase (Fig. 3A) and the
calculated Ki was 0.52 m. The activity of this enzyme was
also reduced by progressive concentrations of bicarbonate. The
rate of the reaction catalyzed by succinyl CoA synthetase was
also reduced from 7.31 to 3.41 smol/gImin by acetazolamide
concentrations up to 2 mrvi (Fig. 2B) as well as by increments in
bicarbonate concentration, but not altered by various concen-
trations of ammonium. The rate of this reaction was also
reduced by 6% by 0.001 mi.t acetazolamide but was not changed
by 0.0001 m (not shown in Fig. 2). The double—reciprocal
plots of Lineweaver—Burk indicated a competitive inhibition of
acetazolamide on succinyl CoA synthetase (Fig. 3B) and the
calculated Ki was 0.49 m. The rate of the reactions catalyzed
by malic enzyme and by PEPCK was not modified by the
addition of various concentrations of acetazolamide or ammo-
nium chloride nor by changes in the bicarbonate concentration
in the incubation medium.
1286 Gougoux et a!
Table 7. Effect of acetazolamide on kidney tubules of normal dogs
.Initial substrates
concentration and
incubation pH
.Acetazolamide
concentration
mM
Metabolites production (+) or uptake (—)
Glucose Malate Aspartate
Aiphaketo-
glutarate Succinate
Aiphaketoglutarate 2 mM
0
0.1
1
24±1
21±18
16 18
7±15±la
4 P
—88±5
54 48
PH 7.4
PH 7.1
0
0.1
1
30±2
26 18
18 0.48
10±1
7 P5 P
—113±12
—88 88
—64 78
Succinate 2 mM
PH 7.4
0
0.1
1
28±2
26±1
20 18
25±2
24±2
23 2
0.1±0.7
0.5±0.6
—1.0 0.78
—137±22
—129±24
—109 248
PH 7.1
0
0.1
1
33 2
30 1
22 18
28 2
26 28
23 28
0.6 0.6
1.4 0.6
—0.8 0.68
—142 24
—133 25
—119 248
Malate 2 mM
PH 7.4
0
0.1
1
28±1
24±18
19±0.18
—119±5
PH 7.1
0
0.1
1
33±2
29±la
21±18
—122±7
—117±4
....99÷3a
Values are means SE (N = 4dogs). Results are expressed as micromoles per gram wet weight per 60 minutes and are corrected for zero time.
A positive sign represents production of a metabolite whereas a negative sign depicts uptake.
8 Significant difference from value obtained in the absence of acetazolamide in the flask (P < 0.05)
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Effect of acetazolamide on renal ammoniagenesis and
glutamine metabolism in vivo
The present data indicate that most of the acute reduction in
the urinary excretion of ammonium observed in dogs during the
Fig. 2. Effect of various concentrations of
acetazolamide on the rate of the reactions
catalyzed by aiphaketoglutarate
dehydrogenase (A) and by succinyl-CoA
synthetase (B). The enzymatic activities are
expressed as percentages of the activity
observed in the absence of acetazolamide.
urinary alkalinization resulting from acetazolamide is due to an
almost quantitative diversion of ammonium from the urine to
the renal venous blood. Indeed, because the modest decrease in
the absolute rate of ammoniagenesis and glutamine extraction is
proportional to the decrement in GFR and renal blood flow,
these parameters are not changed or only slightly changed when
100
A B
20
0
iO- 102
Acetazolamide, M
Discussion
10 10 10 10 2
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A B
Fig. 3. Kinetics of acetazolamide inhibition of dog kidney cortex
aiphaketoglutarate dehydrogenase (A) and succinyl-CoA synthetase(B). The concentrations of added acetazolamide were 0.1 mM, 0.3 msi,
0.5 mM, 1 m and 2 m (numbers close to each regression line), With
0.1 mM acetazolamide, an inhibitory effect on aiphaketoglutarate dehy-
drogenase could not be found and the regression line is not presented.
Velocity is expressed as micromoles of alphaketoglutarate or succinate
metabolized per gram of fresh tissue per minute. Data lines were
calculated by linear regression analysis, Lines with 1 m and 2 mM
acetazolamide were calculated with additional data points that are not
illustrated.
expressed per 100 ml GFR. Glutamine extraction and ammonia
production can be usefully expressed per 100 ml GFR because
glutamine oxidation provides energy for proximal sodium reab-
sorption and is therefore directly related to GFR [28, 33]. Thus,
under control conditions a direct relationship exists between
glutamine metabolism and renal hemodynamics, and the ex-
pression of metabolic events per 100 ml GFR allows an exam-
ination of these processes at a constant proximal sodium—
reabsorption. This relation may be altered by the acetazol-
amide—induced inhibition of sodium and bicarbonate reabsorp-
tion. Indeed, it must be kept in mind that the utilization of a
proximal diuretic like acetazolamide will reduce proximal so-
dium reabsorption, and could consequently distort the relation-
ship between glutamine metabolism and GFR. The absence of
change in net renal glutamine utilization may therefore reflect a
change in the metabolic cost of proximal sodium reabsorption.
It appears that acetazolamide, as recently observed in the
isolated perfused kidneys of acidotic rats [9], has only a small
specific effect on renal ammoniagenesis. The slight 8% reduc-
tion in renal ammoniagenesis per 100 ml GFR observed during
acetazolamide infusion in our chronically acidotic dogs is more
modest but in accord with the 28% fall calculated from the data
of Risquez, Hernandez and Preuss [5] in seven mildly—acidotic
dogs.
The present study confirms previous data reported in the dog
[34—36] showing that a complete dissociation between urinary
ammonium excretion and renal ammoniagenesis can occur in
some situations. Indeed, a reduction in ammonium excretion
may be accompanied by a decrease, no change or even a
marked increment in total ammonium production, as recently
demonstrated in maleate—treated dogs in which a drastic reduc-
tion in urinary ammonium excretion was accompanied by a
markedly—accelerated renal ammoniagenesis [37]. This disso-
ciation between urinary ammonium excretion and renal ammo-
niagenesis indicates that this latter process cannot be extrapo-
lated from urinary excretion of ammonium.
In vitro, the addition of acetazolamide to a suspension of dog
[38] or rat [39] kidney tubules has been reported to increase the
intracellular pH. In vivo, a recent study performed in the rat has
demonstrated that the cytosolic pH of proximal tubular cells is
significantly increased by acetazolamide infusion [40]. How-
ever, we could not detect any significant change in three
indirect parameters thought to reflect intracellular pH and
significantly modified in acid—base disorders [41—43]: the renal
ammoniagenesis per 100 ml GFR, the renal cortical concentra-
tion of citrate and the urinary citrate excretion. More specifi-
cally, these findings stand in sharp contrast with the significant
fall in renal glutamine extraction and ammoniagenesis, and the
rise in the urinary excretion of citrate and its renal cortical
concentration recently observed in dogs with acute or chronic
metabolic alkalosis [43, 44]. Our data are thus compatible with
the hypothesis that the intramitochondrial pH or the hydrogen
ion gradient between the more alkaline mitochondrial matrix
and the cytosol [45] are not changed significantly by acetazol-
amide.
This lack of effect of acetazolamide on renal ammoniagenesis
in the dog contrasts with the reduction of glutamine utilization
and ammonia production described in the rat [4] and attributed
to a direct inhibition of cytoplasmic glutaminase and y-
glutamyltransferase [4] and of y.glutamyl transpeptidase [7].
However such an inhibition of these three enzymes could not be
reproduced by Chapman and Hoover [8]. It should be noted
that y-glutamyltransferase is absent in the dog kidney [46]. In
the present study, the rate of the reaction catalyzed by mito-
chondrial glutaminase was not influenced by the addition of
various concentrations of acetazolamide. Thus the reduced
ammoniagenesis may result mostly from hemodynamic changes
induced by acetazolamide as well as from a direct inhibitory
effect of the drug itself on ammoniagenesis (after the gluta-
minase step).
The only significant metabolic change induced in vivo by
acetazolamide is an increased renal lactate utilization in normal
dogs presenting a marked bicarbonaturia. The inhibition by
acetazolamide of sodium reabsorption in the dog proximal
convoluted tubule [47] increases sodium delivery and probably
its reabsorption in more distal parts of the nephron; this could
explain the increased utilization of lactate. Indeed, it has been
recently suggested that lactate is the preferential fuel for the
distal nephron [48].
Effect of acetazolamide on the renal cortical metabolites
profile in chronically acidotic dogs
Acetazolamide reduces the renal cortical concentrations of
glutamine, glutamate, succinate, fumarate, malate and aspar-
tate in acidotic dogs. Because the renal glutamine utilization
was not accelerated but reduced, the 40% fall in the renal
cortical glutamine concentrations in both normal and chroni-
cally acidotic dogs possibly reflects a decreased cellular uptake
of this amino acid (either at the luminal membrane or at the
Ketoglutarate Succinate
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antiluminal one) induced by the observed hemodynamic
changes. The drastic fall in malate concentration is in agree-
ment with that of fumarate (in equilibrium with malate) and of
aspartate (in equilibrium with oxaloacetate/malate). The
marked fall in these metabolites is specific for the kidneys of
chronically acidotic dogs utilizing rapidly glutamine and is not
due to PNH3 changes because it cannot be reproduced by
increasing renal cortical ammonium—concentration. Such a fall
may be due to a decreased cellular uptake of these metabolites
either at the antiluminal membrane (by reduction of the renal
blood flow) or at the luminal one (by reduction of the GFR).
Alternatively, this fall could result from specific metabolic
changes through the following three mechanisms: first, an
accelerated loss of one or several of these substrates by
alteration in the cell permeability; second, an accelerated
metabolism of these substrates; and third, a reduced production
of malate/oxaloacetate from glutamine (and not from lactate).
An accelerated loss of malate and/or oxaloacetate may have
contributed to the drastic fall of the renal cortical concentration
of malate following acetazolamide administration in chronically
acidotic dogs. Even il we could not detect a release of malate
and/or aspartate into the urine or the renal vein following
acetazolamide, the large renal blood—flow does not allow us to
rule out such a mechanism. However the lack of malate in the
supernatant fluid when tubules were incubated with malate and
the lack of effect of acetazolamide when lactate was the source
of malate and oxaloacetate does not favour a change in cell
permeability and rather suggests a specific effect on the meta-
bolic pathway between glutamine and malate/oxaloacetate.
Acetazolamide could also accelerate directly the cellular
metabolism of either malate into pyruvate (reaction catalyzed
by the malic enzyme) or oxaloacetate into phosphoenolpyru-
vate (reaction catalyzed by the PEPCK): the Km of one or two
of these enzymes could be reduced or their Vmax could be
increased by acetazolamide. An accelerated gluconeogenesis
seems unlikely because renal cortical phosphoenolpyruvate
concentration fell following acetazolamide, suggesting not a
stimulation but a reduction of gluconeogenesis. Furthermore
this mechanism is not supported by the reduction in gluconeo-
genie flux induced by acetazolamide in vitro. Therefore, in vivo
an inhibitory effect of acetazolamide at some enzymatic step(s)
between glutamine and malate/oxaloacetate remains the most
likely possibility. The site of action of acetazolamide had to be
further studied in vitro. Finally, we cannot rule out the hypoth-
esis that the reduction in renal blood flow might be responsible,
at least in part, for the observed fall in the renal cortical
concentrations of various critical metabolites in the present
studies in vivo.
Effect of acetazolamide in in vitro studies
The addition of acetazolamide to the incubation medium
reduced the utilization of (and gluconeogenesis from) each of
the five substrates studied, that is, glutamine, lactate, alphake-
toglutarate, succinate or malate. One m acetazolamide de-
creased ammoniagenesis from glutamine more markedly than
the 10% reduction observed by Tannen and Ross in the rat [9].
Acetazolamide reduced malate production from glutamine,
alphaketoglutarate and succinate, suggesting a reduced flux
between glutamine and malate, between alphaketoglutarate and
malate and between succinate and malate. These reduced fluxes
are consistent with the reduced fraction of glutamine metabo-
lized through the GLDH pathway (and consequently the flux
between alphaketoglutarate and malate/oxaloacetate, the main
route by which glutamine is metabolized into glucose or C02)
and the reciprocal increase in the glutamine converted to
glutamate, alanine or aspartate. These reduced fluxes might
theoretically result from the inhibition of one or more of the
three non-equilibrium enzymes present between glutamine and
malate, that is, glutaminase, alphaketoglutarate dehydrogenase
and succinyl CoA synthetase. Furthermore, gluconeogenesis
was also reduced from these substrates, a finding that cannot be
accounted for solely by a reduced substrate availability because
gluconeogenesis from malate was also significantly decreased
(as previously reported in the rat [9]). Therefore, a reduced flux
between malate and glucose (possibly at the PEPCK level) must
also be invoked and could account for the reduced renal cortical
concentration of phosphoenolpyruvate. When lactate is used as
substrate and oxaloacetate is produced through the pyruvate
carboxylase pathway, an inhibition of the malate/oxaloacetate
metabolism towards glucose synthesis is observed together
with an acetazolamide—induced rise in malate accumulation in
vitro. In summary, studies with kidney tubules suggest that
several enzymes between glutamine and glucose could be
affected by acetazolamide along the ammoniagenic and gluco-
neogenic pathways, and that the inhibited gluconeogenesis
would not be the only factor responsible for the reduced
ammoniagenesis as proposed in the rat [9].
Effect of acetazolamide on various enzymatic activities along
the ammonia genic and gluconeogenic pathways
To explore directly an eventual effect of acetazolamide on the
enzymes named above, the possible influence of acetazolamide
on the activity of the following enzymes was directly studied:
glutaminase, glutamate dehydrogenase, alphaketoglutarate de-
hydrogenase and succinyl CoA synthetase, PEPCK and the
malic enzyme. The absence of effect on the rate of the reactions
catalyzed by glutaminase and by glutamate dehydrogenase
rules out an effect between glutamine and alphaketoglutarate.
However, the inhibition by acetazolamide of the reaction
catalyzed by alphaketoglutarate dehydrogenase (Fig. 2) is in
agreement with the significant reduction in alphaketoglutarate
utilization observed in isolated kidney tubules incubated with
aiphaketoglutarate. This inhibitory effect of acetazolamide on
alphaketoglutarate dehydrogenase has not been reported previ-
ously. Furthermore, the rate of the reaction catalyzed by
succinyl CoA synthetase was reduced by acetazolamide (Fig.
2), a finding in agreement with the modest reduction in sue-
cinate utilization seen when isolated kidney tubules were incu-
bated with succinate.
In this respect, it is of interest that acetazolamide has
produced a marked reduction in the rate of oxygen consumption
by mitochondria isolated either from rat [49] or from dog [50]
kidneys. It should, however, be emphasized that the concen-
trations of acetazolamide necessary to inhibit significantly
alphaketoglutarate dehydrogenase and succinyl CoA synthe-
tase are much higher than the range of concentrations around
0.1 m previously observed in the plasma [15] or in the renal
cortex [12] of dogs infused the amounts of acetazolamide used
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in the present in vivo study. In contrast, intracellular concen-
trations of acetazolamide above these Ki values were probably
achieved with acetazolamide in vitro. The unchanged renal
cortical alphaketoglutarate concentration following acetazol-
amide administration might reflect the absence of a significant
enzymatic inhibition in our in vivo study. Alternatively, the
alphaketoglutarate concentration may be maintained by active
near—equilibrium alanine aminotransferase and aspartate ami-
notransferase systems of the kidney tissue. In any case it is not
possible to extrapolate from the in vitro data to predict the
effects of acetazolamide on the renal metabolism in vivo,
An inhibition of the reaction catalyzed by the malic enzyme
cannot be observed in vitro: the apparent Km of malic enzyme
for malate was not modified by the addition of various concen-
trations of acetazolamide or ammonium chloride, nor by
changes in the bicarbonate concentration in the incubation
medium. This may not rule out an effect of acetazolamide in
situ. Similarly no effect of acetazolamide was observed on the
rate of the reaction catalyzed by PEPCK. Nevertheless a
significant reduction in gluconeogenesis from malate was ob-
served in isolated kidney tubules incubated with a good source
of oxaloacetate, that is, with malate. To reconcile these obser-
vations, one may speculate that a significant fraction of the
gluconeogenic flux may occur through the mitochondrial form
of the PEPCK enzyme because in the dog the major fraction of
this enzyme is located inside the mitochondria [51].A limitation
in bicarbonate availability inside the mitochondria due to car-
fumarate, malate and aspartate in chronically acidotic dogs may
be due in part to specific inhibition of alphaketoglutarate
dehydrogenase and succinyl CoA synthetase enzymes. An
additional effect of acetazolamide on gluconeogenesis may
occur. Therefore acetazolamide is not only a specific inhibitor
of carbonic anhydrase. The study of this problem at the tubule
and/or enzyme levels has provided a mechanistic hypothesis to
understand the modest anti-ammoniagenic effect of acetazol-
amide.
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